AdAlta and Crossbeta Enter Alzheimer’s Disease-Specific Shark Antibodies Agreement

AdAlta and Crossbeta Enter Alzheimer’s Disease-Specific Shark Antibodies Agreement
AdAlta and Crossbeta Biosciences have entered into a commercialization agreement, granting Crossbeta with a license to three beta-amyloid oligomer (AßO)-specific shark antibodies, considered to have disease-specific potential for the diagnosis and treatment of Alzheimer’s disease (AD). These three shark antibodies were identified under a December 2013 agreement between the two companies. The research and development

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *